Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

990 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML).
Zander AR, Kröger N, Schleuning M, Finke J, Zabelina T, Beelen D, Schwerdtfeger R, Baurmann H, Bornhäuser M, Ehninger G, Fauser AA, Kiehl M, Trenschel R, Ottinger HD, Bertz H, Berger J, Kolb HJ, Schaefer UW. Zander AR, et al. Among authors: kroger n. Bone Marrow Transplant. 2003 Aug;32(4):355-61. doi: 10.1038/sj.bmt.1704157. Bone Marrow Transplant. 2003. PMID: 12900771
Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Kröger N, Krüger W, Wacker-Backhaus G, Hegewisch-Becker S, Stockschläder M, Fuchs N, Rüssmann B, Renges H, Dürken M, Bielack S, de Wit M, Schuch G, Bartels H, Braumann D, Kuse R, Kabisch H, Erttmann R, Zander AR. Kröger N, et al. Bone Marrow Transplant. 1998 Dec;22(11):1029-33. doi: 10.1038/sj.bmt.1701498. Bone Marrow Transplant. 1998. PMID: 9877263
Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow.
Zander AR, Zabelina T, Kröger N, Renges H, Krüger W, Löliger C, Dürken M, Stockschläder M, de Wit M, Wacker-Backhaus G, Bielack S, Jaburg N, Rüssmann B, Erttmann R, Kabisch H. Zander AR, et al. Among authors: kroger n. Bone Marrow Transplant. 1999 May;23(9):889-93. doi: 10.1038/sj.bmt.1701745. Bone Marrow Transplant. 1999. PMID: 10338043 Clinical Trial.
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR. Kröger N, et al. Bone Marrow Transplant. 2000 Oct;26(7):711-6. doi: 10.1038/sj.bmt.1702598. Bone Marrow Transplant. 2000. PMID: 11042650
Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Dürken M, Graf von Finkenstein F, Erttmann R, Kabisch H, Schafhausen P, Jaburg N, Löliger C, Zander AR. Kröger N, et al. Ann Hematol. 2001 Apr;80(4):209-15. doi: 10.1007/s002770000269. Ann Hematol. 2001. PMID: 11401086
Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Schafhausen P, Jaburg N, Löliger C, Schäfer P, Hinke A, Zander AR. Kröger N, et al. Br J Haematol. 2001 Jun;113(4):1060-71. doi: 10.1046/j.1365-2141.2001.02849.x. Br J Haematol. 2001. PMID: 11442503 Free article.
990 results